Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference
August 29 2018 - 7:00AM
Akcea Therapeutics, Inc.(NASDAQ:AKCA), an affiliate of Ionis
Pharmaceuticals, Inc., today announced that management will present
a company overview at the Wells Fargo Healthcare Conference at 4:10
p.m. ET on Wednesday, September 5, 2018 in Boston.
A live webcast of the presentation will be available on the
“Media & Investors” section of the Akcea website,
www.akceatx.com. The replay will be available within 24 hours and
will be archived for a limited time.
ABOUT AKCEA THERAPEUTICS Akcea Therapeutics,
Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a
biopharmaceutical company focused on developing and commercializing
drugs to treat patients with serious and rare diseases. Akcea is
advancing a mature pipeline of six novel drugs, including
TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen),
AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, AKCEA-APOCIII-LRx, and
AKCEA-TTR-LRx, all with the potential to treat multiple diseases.
All six drugs were discovered by and are being co-developed with
Ionis, a leader in antisense therapeutics, and are based on Ionis’
proprietary antisense technology. TEGSEDI is approved in the E.U.
for the treatment of stage 1 or stage 2 polyneuropathy in adult
patients with hereditary transthyretin amyloidosis (hATTR) and is
currently under regulatory review in the U.S. and Canada. WAYLIVRA
is also under regulatory review in the E.U. and Canada for the
treatment of familial chylomicronemia syndrome, or FCS, and is
currently in Phase 3 clinical development for the treatment of
people with familial partial lipodystrophy, or FPL. Akcea is a
global company headquartered in Cambridge, Massachusetts.
Additional information about Akcea is available
at www.akceatx.com.
FORWARD-LOOKING STATEMENT This press release
includes forward-looking statements regarding the business of Akcea
Therapeutics, Inc. and the therapeutic and commercial potential of
TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and other
products in development. Any statement describing Akcea’s goals,
expectations, financial or other projections, intentions or beliefs
is a forward-looking statement and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics, and in the endeavor of
building a business around such drugs. Akcea’s forward-looking
statements also involve assumptions that, if they never materialize
or prove correct, could cause its results to differ materially from
those expressed or implied by such forward-looking statements.
Although Akcea’s forward-looking statements reflect the good faith
judgment of its management, these statements are based only on
facts and factors currently known by Akcea. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Akcea’s programs are described in
additional detail in Akcea’s annual report on Form 10-K for the
year ended December 31, 2017, and most recent Form 10-Q quarterly
filing, which are on file with the SEC. Copies of this and other
documents are available from the Company.
In this press release, unless the context requires otherwise,
“Ionis,” “Akcea,” “Company,” “Companies,” “we,” “our,” and “us”
refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis
Pharmaceuticals, Inc. Akcea Therapeutics™, TEGSEDI™,
WAYLIVRA™ are trademarks of Akcea Therapeutics, Inc.
Investor and Media Contact: Kathleen
GallagherVice President of Communications and Investor Relations
(617)-207-8509kgallagher@akceatx.com
Akcea Therapeutics (NASDAQ:AKCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akcea Therapeutics (NASDAQ:AKCA)
Historical Stock Chart
From Sep 2023 to Sep 2024